Former Staff Scientist at the Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, Washington, Dr. King has over 25 years of combined academic and private sector scientific research experience including utilizing cell culture and animal model systems to address a wide range of topics including cardiovascular disease, liver disease, thrombosis and cancer. In 1999, he obtained his Ph.D. in Genetics/Molecular Biology from the University of Hawaii at Manoa where he focused on the tumor suppressor and growth regulatory roles of gap junction proteins using cancer cell culture systems and mouse tumor models. Concurrently, he also studied the influence of retinoids and various carotenoids on normal and tumor cell growth/behavior, carcinogenesis and gene regulation. After graduation, he joined the FHCRC as a post-doctoral researcher where he investigated the combined and separate roles of gap junction proteins and cell cycle regulatory proteins on multi-organ tumorigenesis using several genetically-engineered mouse models. In 2004, he was appointed as a Staff Scientist at the FHCRC where he continued research until joining Hawaii Biotech, Inc. (Aiea, HI) as the Director of Cancer Chemoprevention from 2005-2006. Subsequently, he has served as Director of Biological Research (2006-2007) and Senior Director of Biological Research (2007-2009) at Cardax where as VP of Research he currently leads company scientific endeavors and has guided academic collaborations employing various animal models to evaluate drug efficacy in areas including atherosclerosis, thrombosis and liver disease. Dr. King also possesses an M.S. in Biology (Molecular Virology) from San Diego State University studying Rhadoviral transcription processes.